Clinical trial NCT02740114
Conditions: Malignant Neoplasms of Female Genital Organs Gynecologic Cancer
Keywords: Malignant neoplasms of female genital organs Open gynecologic surgery Local wound infiltration Gynecologic cancer Bupivacaine Liposomal Bupivacaine Oxycodone ETH-Oxydose [DSC] OxyContin OxyIR Roxicodone Questionnaires Surveys MD Anderson Symptom Inventory MDASI Pill diary Medication log
Sponsor: M.D. Anderson Cancer Center
Start date: 2016-08-31; Completion date: 2020-07-23
Enrollment: 105 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
Bupivacaine is a drug that is traditionally given as an injection to numb surgical sites. Liposomes are molecules that are similar to fats. Sometimes drugs are combined with liposomes to make them able to stay in the body for longer periods of time. This has been done with bupivacaine to create liposomal bupivacaine.

The goal of this clinical research study is to compare the effects of bupivacaine to those of liposomal bupivacaine when given to patients who are having gynecologic surgery. Researchers want to compare how long the drugs work to numb the wound and how long patients take to recover from surgery.

Detailed description:
Study Arms and Drug Administration:

If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 study arms:

* If you are in Arm 1, you will receive bupivacaine only.
* If you are in Arm 2, you will receive a combination of liposomal bupivacaine and bupivacaine.

You will have an equal (50/50) chance of being assigned to either group. You will not know what you are receiving. However, the study staff will know what you are receiving.

In both cases, the drug(s) will be injected into your skin and tissue at the end of your surgery, right before the wound is closed.

Study Data Collection:

Every day while you are in the hospital recovering from surgery, you will be asked questions about pain, any side effects you may be having, symptoms, and opioid use.

Within 30 days after you leave the hospital, you may also be called and asked about side effects you may be having. If you are called, this call should last about 10-15 minutes. This information may also be collected during a routinely scheduled clinic visit and from the medical record.

Three (3) and 7 days after you leave the hospital, and then 1 time every week after that for a total of 8 weeks, you will be called or emailed and asked questions about any symptoms you may be having. If you are called, each call should last about 10-15 minutes.

If you are also enrolled on the study BS99-094 "Measuring the Symptom Distress of Cancer Patients: Development of a New Assessment System," information from your participation in this study may also be collected and used in that study.

Length of Study:

Your participation on this study will be over 8 weeks after you leave the hospital.

This is an investigational study. Both bupivacaine and liposomal bupivacaine are FDA approved and commercially available. It is investigational to compare the 2 drugs.

Up to 200 participants will be enrolled in this study. All will take part at MD Anderson.

Arms: arm 1: Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.

Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.

Participants complete a pill diary every day for 30 days after hospital discharge.

Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks. arm 2: Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.

Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.

Participants complete a pill diary every day for 30 days after hospital discharge.

Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
Interventions: intervention 1: Bupivacaine intervention 2: Liposomal Bupivacaine intervention 3: Oxycodone intervention 4: Pill Diary intervention 5: Symptom Questionnaire
Intervention descriptions: intervention 1: 150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure. intervention 2: 266 mg injected on each side of the wound at the end of surgery before wound closure. intervention 3: 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain. intervention 4: Participants complete a pill diary every day for 30 days after hospital discharge. intervention 5: Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.

Protocol documents:
Prot_SAP_000.pdf: 
 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 1 of 39 
 
 
 
 
Wound infiltration with liposomal bupivacaine vs. standard wound infiltration with 
bupivacaine in patient’s undergoing open gynecologic surgery on an Enhanced 
Recovery Pathway: a single-blinded, randomized, controlled study 
Sponsor: Pacira Pharmaceuticals, Inc. 
Study Site: MD Anderson Cancer Center 
MD Anderson Protocol #: 2015-1119 
Principal Investigator: 
Department of Gynecologic Oncology & Reproductive Medicine: 
Pedro T. Ramirez, M.D. 
Co-Principal Investigators: 
Department of Gynecologic Oncology & Reproductive Medicine: 
Larissa A. Meyer, M.D. 
Department of Anesthesiology & Perioperative Medicine: 
Javier D. Lasala, M.D. (Co-PI) 
Collaborators: 
Department of Anesthesiology & Perioperative Medicine: 
Gabriel E. Mena, M.D. 
Department of Biostatistics: 
Brandelyn Pitcher 
Diana Urbauer 
Department of Symptom Research 
Xin S. Wang, M.D. 
Qiuling Shi, PhD. 
Department of Clinical Pharmacy Programs 
Katherine Cain, PharmD 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 2 of 39 
 
 
 
 
Background: 
Enhanced Recovery Pathways (ERP) has been shown to be safe for patients undergoing 
major gynecologic oncology operations. A successful ERP program has been associated 
with reduced length of hospital stay, increased patient satisfaction, and lower costs [1]. 
The multimodal ERP aims at a more evidence-based perioperative care pathway while 
challenging routine clinical practices [2]. One of the key elements of the Enhanced 
Recovery Pathways after Gynecologic Surgery Program at MD Anderson Cancer Center 
is preemptive analgesia and perioperative multi-modal opioid sparing strategies. This 
element is imperative as it reduces opioid related adverse events (ORADE) [3].  
To achieve these goals, ERP programs focus primarily on reducing perioperative stress, 
achieving satisfactory pain control, resumption of normal gastrointestinal function, and 
early mobilization. Based on all of these key elements, we have implemented the ERP 
program shown in Tables 1-3 in the Department of Gynecologic Oncology & Reproductive 
Medicine at MD Anderson Cancer Center.   
On the basis of current data, it appears that implementation of our ERP program may 
result in an overall improvement in postoperative outcomes.  However, more studies are 
needed that include a consistent strategy with an evaluation of the key elements of care 
implemented in the perioperative period, and evaluating the outcomes based on the 
adherence to the key elements.  
Recently, Nick et al. [4] conducted a study to evaluate the implementation of a 
multidisciplinary Enhanced Recovery Pathways (ERP) for all patients undergoing 
exploratory laparotomy for gynecologic indications in the Department of Gynecologic 
Oncology and Reproductive Medicine at MD Anderson Cancer Center.  Consecutive 
patients managed under an ERP undergoing exploratory laparotomy between 
11/3/2014 and 1/15/2015 were compared to historical controls (May-November 2014).  
Interventions included, but were not limited to, allowing oral intake of fluids up to 2 hours 
before induction of anesthesia; pre-, intra-, and post-operative euvolemia as well as 
opioid-sparing analgesia and anesthesia; wound infiltration with bupivacaine, early 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 3 of 39 
 
 
 
 
ambulation and regular diet on the day of surgery.   A total of 58 women in the 
enhanced recovery group were compared with women in the control group.  Thus far, 
enhanced recovery has resulted in a 1-day reduction in hospital stay (median LOS pre-
implementation: 4 days [2-27] vs. post-implementation: 3 days [1-11], p=0.001) with 
stable readmission rates (pre-ERP: 11.7% vs. post-ERP: 12%, p=1.00).  No differences 
were observed in rates of pre-operative and post-operative complications (GI: pre-ERP 
24% vs. post-ERP 15%, p=0.26; GU: pre-ERP 6% vs. post-ERP 13%, p=0.22; Neuro: 
pre-ERP 0.01% vs. post-ERP 0.02%, p=1.0; Hematologic: pre-ERP 6% vs. post-ERP 
14%, p=0.13).  Among those with advanced recurrent ovarian cancer (pre-ERP 57%; 
post-ERP 45%), median length of return to intended oncologic therapy (RIOT) was 30 
days (range 15-52) pre-ERP compared to 22 days (range 20-41) post-ERP (p=0.08).  
The investigators concluded that implementation of an ERP at a tertiary cancer center is 
feasible with noted benefits to patient outcomes.  
Moving forward, successful health care organizations will be patient-centered, 
multidisciplinary, process oriented and outcome-based.  To that end, patient reported 
outcome measures (PROs) will influence the way we deliver medical care in the future 
of health care reform.  PROs have long represented the gold standard for quality of life 
and patient satisfaction.  Recently, they have also become an area of increasing focus 
in comparative effectiveness research, health care quality assessments, and as 
endpoints in clinical trials.  [5-8] The Center for Medical Technology Policy (CMTP) 
recommends that prospective clinical comparative effectiveness research (CER) 
capture the subjective patient experience. [5]  
We propose implementing the use of liposomal bupivacaine (Exparel) in our ERP for 
longer duration of analgesia and further reduction in opioid administration. We will be 
looking at the percentage of patients that are opioid free at 48 hours following surgery in 
the proposed study arms as a primary outcome.  
Currently, there is a gap in knowledge in that there is no concrete evidence to support 
whether the infusion of liposomal bupivacaine directly into the wound after laparotomy 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 4 of 39 
 
 
 
 
provides the most effective analgesia when compared to standard bupivacaine.  The 
implementation of liposomal bupivacaine with its prolonged analgesic effects in an 
enhanced recovery pathway has the potential to improve pain management and 
decrease opioid administration. Given such gap in knowledge and the fact that there is 
considerable cost difference between liposomal bupivacaine and standard bupivacaine, 
our goal is to investigate whether in fact there is an added benefit to liposomal 
bupivacaine in our ERP patients undergoing gynecologic surgery. We aim to answer 
this very important question through our proposed study. 
Official Title:  
Wound infiltration with liposomal bupivacaine vs. standard wound infiltration with 
bupivacaine in patient’s undergoing open gynecologic surgery on an Enhanced 
Recovery Pathway: a single-blinded, randomized, controlled study 
Our hypothesis is that we will see an absolute increase of 20% in the proportion of 
patients opioid-free at 48 hours after end of surgery in the liposomal bupivacaine arm 
compared with the bupivacaine arm, regardless of the proportion of patients opioid-free 
in the bupivacaine arm. 
Objective: 
To compare the analgesic efficacy and functional recovery of local wound infiltration 
using liposomal bupivacaine compared with wound infiltration with bupivacaine in 
patients undergoing open gynecological surgery (laparotomy) on an enhanced recovery 
pathway.  
Study Arms and Assigned Interventions: 
This will be a randomized study with patients randomized equally to the following 2 
arms:  
Arm 1: Local wound infiltration with 0.25% bupivacaine immediately prior to wound 
closure (Control) 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 5 of 39 
 
 
 
 
Arm 2: Local wound infiltration with liposomal bupivacaine and 0.25% 
bupivacaine admixed immediately prior to wound closure 
Study Arms and Procedures: 
At the completion of surgery and prior to incision closure, a total of 60 mL of 0.25% 
bupivacaine without epinephrine (Arm 1) or a volume specific to incision size of 
liposomal bupivacaine [0.25% bupivacaine and liposomal bupivacaine] (Arm 2) will be 
infiltrated into the wound as described below in the Detailed Dosing Description 
(Page 9).   
Study Type: 
This will be a randomized, controlled single blind (patient) interventional study.  
The benefit of a randomized trial in this setting lies in the fact that our group has 
achieved excellent results in our Enhanced Surgical Recovery Program in gynecologic 
oncology using standard bupivacaine.  However, we aim to investigate whether 
liposomal bupivacaine will provide additional benefit to our patients as it pertains to pain 
management and impact on opioid consumption. 
Study Design: 
Endpoint Classification:  Analgesic efficacy and functional recovery 
Intervention Model:  Double intervention 
Masking: Single blinded (patient)  
Primary Purpose: Treatment  
Primary Outcome Measure:  
1) Proportion of patients opioid-free at 48 hours after surgery. 
Secondary Outcome Measures:  
1) 
Number of opioid-free days (POD0, POD1, POD2, POD3) 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 6 of 39 
 
 
 
 
2) 
Morphine Equivalent Daily Dose (MEDD): This will be calculated based on the total 
daily consumption of opioids. We will record the MEDD on POD1, POD2, and 
POD3 and MEDD will be calculated as the area under the dose-time curve (AUC). 
3) 
Patient Reported Outcomes (PROs) with MD Anderson Symptom Inventory 
(MDASI) at baseline, daily while inpatient, day 3 (+/- 1 day) and 7 (+/- 1 day) after 
discharge and then weekly (+/- 3 days) to complete 8 weeks (+/- 3 days) from the 
date of surgery. Failure to complete any questionnaires will not be considered a 
deviation requiring reporting. While the patient is admitted, research personnel 
may assist the patient to complete the MDASI with verbal responses from the 
patient (Appendix A). 
4) 
Assessment of pain will be performed daily after surgery every 4 +/- 2 hours while 
the patient is awake, up to 96  hours while in-hospital using the 0-10 Numeric Pain 
Rating Scale (Appendix B). If patient is discharged before 96 hours, pain will be 
assessed once a day via Interactive Voice Response (IVR) system, phone call or 
electronic survey until completion of 96 hours post-surgery [9]. If the participant is 
contacted by phone or if the assessment is administered in person, the information 
will be directly entered into REDCap. In the circumstance that the system is down, 
the patient refuses to respond electronically or there is no access to an electronic 
device, the use of paper forms will be permitted. Pain will be measured as the area 
under the pain-time curve (AUC).  
5) 
Pain goals stated by the patient will be collected daily while in-hospital as routinely 
performed by nursing staff.  
6) 
Time to first post-operative opioid administration after end of anesthesia. 
7) 
Perioperative opioid administration (opioid type and dose)  
8) 
Days to “discharge ready”. This will be the number of days from surgery to when 
the patient is considered ready for discharge to home. (Appendix C). 
9) 
Postoperative complications: We will only collect postoperative complications that 
are felt to be related to either study drug at 30-days post-surgery and may include 
the following: 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 7 of 39 
 
 
 
 
a) Central Nervous System Complication  
• Anxiety 
• Delirium (Acute altered and fluctuating mental status with features of 
inattention and an altered level of consciousness.) 
• CVA  
• Numbness and/ or weakness (extremities) 
• Other 
b) Respiratory Complication  
• Dyspnea 
• Hypoxia 
• Pneumonia 
• Pulmonary embolism  
• Reintubation  
• Pulmonary edema 
• Pneumothorax 
• Other  
c) Cardiovascular Complication  
• Arrhythmia 
• CHF 
• Myocardial Infarction  
• Arrest/CPR 
• Hypertension  
• Hypotension  
• Tachycardia 
• Syncope 
• Other  
d) Gastrointestinal Complication 
• Ileus 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 8 of 39 
 
 
 
 
• Diarrhea 
• Constipation  
• Obstruction  
• Anastomotic Leak 
• Nausea and vomiting 
• Hematemesis 
• Coffee ground emesis 
• Small bowel perforation  
• Large bowel perforation  
• Enterocutaneous fistula 
• Recto-vaginal fistula 
• Other  
e) Liver and Pancreas Complication  
• Biliary obstruction  
• Pancreatic leak  
• Pancreatitis 
• Other  
f) Renal/GU Complication  
• Acute renal risk: 1.5 fold increase in the serum creatinine or GFR 
decrease by 25% or urine output <0.5 mL/kg per hour for 6 hours.  
• Acute renal injury: Twofold increase in serum creatinine, or GFR decrease 
by 50% or urine output <0.5 mL/kg per hour for 12 hours.  
• Acute renal failure: Threefold increase in serum creatinine, or GFR 
decrease by 75%, or urine output of <0.3 mL/kg per hour for 24 hours or 
anuria for 12 hours.  
• Urinary tract infection  
• Urinary retention  
• Urinary leak  


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 9 of 39 
 
 
 
 
• Urinoma  
• Other  
g) Endocrine Complication  
• Hyperglycemia 
• Other 
h) Metabolic Complication  
• Electrolyte Imbalance  
• TPN  
• Other  
i) Wound Complication  
• Surgical site infection  
• Dehiscence (Note: includes fascia separation)  
• Other site infection  
• Pelvic Abscess 
• Skin separation  
• Wound seroma  
• Other 
j) Sepsis Complication  
• Sepsis 
• Septic shock  
k) Hematologic Complication  
• Deep vein thrombosis 
• Anemia/transfusion  
• Thrombocytopenia  
• Neutropenia 
• Other  
l) Other Complication  


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 10 of 39 
 
 
 
 
Data on complications will be collected per occurrence while in-patient, during patient 
visits, or at 30 day (+/- 3 days) follow up through telephone communication, by review of 
electronic medical records, and from pharmacy reports.  
10) Complication grade will be determined using the Clavien-Dindo Surgical 
Complication Grading System (Appendix D).  
Detailed Dosing Description:  
This is a prospective, randomized, single-blinded study evaluating the analgesic efficacy 
of liposomal bupivacaine (EXPAREL) in conjunction with 0.25% bupivacaine used for 
local wound infiltration versus local wound infiltration with 0.25% bupivacaine 
undergoing open gynecological procedures (laparotomy) on an Enhanced Recovery 
Pathway. In Arm 1, patients will receive 150 mg of bupivacaine alone as this is the 
highest dose that can be given to patients that is below the level of potential toxicity. 
Hence, it allows the surgeons to have more volume of infiltration to cover more 
receptors along the surgical incision. In Arm 2, patients will receive 266 mg of liposomal 
bupivacaine + 150 mg of bupivacaine. The liposomal bupivacaine will release more 
slowly over 48 hours and the bupivacaine will provide immediate coverage.  We are 
always concerned about patient safety so the dose of plain bupivacaine in any arm 
cannot be higher than 150 mg and we have adjusted for this in Arm 2 in order to ensure 
patient safety due to potential risk of neurologic and cardiac toxicity. In addition to this 
we are following the new updated prescribing information, which states bupivacaine HCl 
administered together with EXPAREL may impact the pharmacokinetic and/or 
physicochemical properties of EXPAREL, and this effect is concentration dependent. 
Therefore, bupivacaine HCl and EXPAREL may be administered simultaneously in the 
same syringe, and bupivacaine HCl may be injected immediately before EXPAREL as 
long as the ratio of the milligram dose of bupivacaine HCl solution to EXPAREL does 
not exceed 1:2. In our study we are administering them simultaneously. We are 
maintaining a 1:2 ratio as follows: The bupivacaine contained in EXPAREL® is free-
base bupivacaine. This differs from other frequently used amide-type, bupivacaine-


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 11 of 39 
 
 
 
 
based local anesthetics which contain the salt form of bupivacaine, bupivacaine HCl. 
Therefore, 266 mg of bupivacaine free base is chemically equivalent to 300 mg of 
bupivacaine HCl. After discussions with the FDA, it was recommended that the dosing 
of EXPAREL be expressed in terms of free-base bupivacaine (266 mg) rather than in 
bupivacaine HCl (300 mg) equivalents. Hence, for our study the bupivacaine HCl 
contents of Exparel are 300 mg, simultaneously injected with 150 mg of bupivacaine 
HCl we are at the 1:2 ratio aforementioned.  
 
 
Arm 2 Summary Table: 
Summary 3.5 inch 
needle 
Large Incision 
Medium Incision 
Small Incision 
Incision length (cm)  
 >31 
25-30  
<24  
Total Volume (mL) 
275 
220 
165 
Subdermal (cc) 
55 
40 
35 
Above Fascia (cc) 
220 
180 
130 
Exparel Volume 
(mL) 
20 
20 
20 
Bupivacaine 
volume (mL) 0.25% 
60 
60 
60 
Additional saline * 
(mL) 
195 +/- 10 
140 +/- 10 
85 +/- 10  
*If the volume of normal saline changes within the allowed parameters, the total volume 
will be equally modified and reflected in a greater/lower volume injected either 
subdermal or above fascia 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 12 of 39 
 
 
 
 
Arm 1:  
On the bupivacaine arm 0.25% bupivacaine will be injected in an even volume of 60 mL 
(150 mg total dose) as follows: 
• 20 mL fascial injection on each side of the wound in a fan-like fashion, 
• 10 mL skin injection on each side of the wound. 
Arm 2:  
For the arm with local infiltration with 0.25% bupivacaine and liposomal bupivacaine 
administered simultaneously, the 266 mg (20 mL, 1.3% of undiluted drug) will be diluted 
in a volume of 60 mL 0.25% bupivacaine (150 mg) in addition to normal saline. The 
addition of saline will be dependent on the size of the incision as outlined in the 
summary table above (Page 11). This admixture will be injected as follows: 
•     Above fascial injection on each side of the wound in a fan-like fashion 
 
•     Subdermal injection on each side of the wound in a fan-like fashion. 
The total amount to be injected at each injection site is determined by the incision length 
and the detailed dosing is provided in the summary table (Page 11). 
 
Eligibility: 
Inclusion Criteria: 
• Undergoing an exploratory laparotomy for suspected gynecologic cancer, which 
includes metastatic disease from neoplasia originating in other organs  
• Planned participation in the Gynecologic Enhanced Recovery Pathway 
• Female 18 years of age or older. 
• Patient must be able to read and speak English 
• Consents to being part of a randomized, single-blinded study 
• Patient has physical and mental capabilities to take part in study 
• Bilirubin less than or equal to 1.5 × ULN; SGOT and SGPT ≤2.5 x ULN 
• If the patient is of childbearing potential, the patient must have a negative blood or 
urine pregnancy test within 14 days of surgical treatment on study. 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 13 of 39 
 
 
 
 
Exclusion Criteria: 
• Sensitivity to amide-type local anesthetics  
• Patients on long-acting opioid medications, or scheduled (four or more times a day 
for seven or more days) short-acting opioid medications within the last 30 days 
• Emergency surgery of any type that does not allow for proper time for protocol 
review by the patient 
• Surgery that involves known/anticipated resection of anterior abdominal wall with 
plastic surgery reconstruction 
• Patients undergoing pelvic exenteration 
• Patients undergoing known/anticipated anterior abdominal wall hernia repairs 
• Patients weighing <50 kg 
Pharmacokinetics of Liposomal Bupivacaine:  
Absorption 
Following its release from the liposomal bupivacaine particles, the rate of systemic 
absorption of bupivacaine is dependent upon the total dose of drug administered, the 
route of administration, and the vascularity of the administration site.  
Distribution 
After bupivacaine has been released from liposomal bupivacaine and is absorbed 
systemically, bupivacaine distribution is expected to be the same as for any bupivacaine 
HCl solution formulation.  To some extent, local anesthetics are distributed to all body 
tissues, with high concentrations found in highly perfused organs such as the liver, 
lungs, heart, and brain.  
The rate and degree of diffusion are governed by: 
• The degree of plasma protein binding 
• The degree of ionization 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 14 of 39 
 
 
 
 
• The degree of lipid solubility 
Metabolism 
Amide-type local anesthetics such as bupivacaine HCl are metabolized primarily in the 
liver via conjugation with glucuronic acid.  Patients with hepatic disease, especially 
those with severe hepatic disease, may be more susceptible to the potential toxicities of 
the amide-type local anesthetics.  Pipecolylxylidine (PPX) is the (largely inactive) major 
metabolite of bupivacaine HCl: approximately 5% of bupivacaine HCl is converted to 
PPX. 
Excretion 
After bupivacaine has been released from liposomal bupivacaine and is absorbed 
systemically, bupivacaine excretion is expected to be the same as for other bupivacaine 
formulations. 
Various pharmacokinetic parameters can be significantly altered by: 
• The presence of hepatic or renal disease 
• Factors affecting urinary pH 
• Renal blood flow 
The kidney is the main excretory organ for bupivacaine and its metabolite; only 6% of 
bupivacaine is excreted unchanged in the urine. 
Hepatic Impairment 
The effects of decreased hepatic function on bupivacaine pharmacokinetics following 
administration of liposomal bupivacaine were studied in patients with moderate hepatic 
impairment. Consistent with the hepatic impairment of bupivacaine, mean plasma 
concentrations were higher in patients with moderate hepatic impairment than in the 
healthy control volunteers.  
Because amide-type local anesthetics, such as bupivacaine, are metabolized by the 
liver, these drugs should be used cautiously in patients with hepatic disease. Patients 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 15 of 39 
 
 
 
 
with severe hepatic disease, because of their inability to metabolize local anesthetics 
normally, are at a greater risk of developing toxic plasma concentrations. 
Renal Impairment 
Bupivacaine is primarily excreted by the kidneys, and the risk of toxic reactions to 
liposomal bupivacaine may be greater in patients with impaired renal function.  
Storage 
Liposomal bupivacaine vials should be stored refrigerated between 2°C to 8°C (36°F to 
46°F). 
Liposomal bupivacaine may be held at a controlled room temperature of 20°C to 25°C 
(68°F to 77°F) for up to 30 days in sealed, intact (unopened) vials. Vials should not be 
re-refrigerated. As a convenience to the pharmacist, each vial label includes space to 
record the date when the vial has been removed from refrigeration. 
Liposomal bupivacaine should not be frozen or exposed to high temperatures (greater 
than 40°C or 104°F) for an extended period. Liposomal bupivacaine should not be 
administered if it is suspected of having been frozen or exposed to high temperatures. 
Risks 
Risks associated with bupivacaine may include: bleeding/oozing from the puncture site, 
bruising at wound site, death, edema, hematoma, and/or infection. 
Benefits 
The benefits of liposomal bupivacaine when compared to standard bupivacaine, is that 
it may provide superior results in reducing the incidence of pain, severity of pain, use of 
analgesics, and a reduced hospital stay.   
 
 
Study Procedures 
Patient Selection and Screening 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 16 of 39 
 
 
 
 
Patients will be screened for study entry in the Gynecologic Oncology Center by a 
Research Data Coordinator (RDC) or Research Nurse.  Patients will be screened 
according to the aforementioned Inclusion/Exclusion Criteria.  Patients will be provided 
with study information and will be allowed ample time to read such information with 
sufficient time for the RDC, Research Nurse, or Principal Investigator to answer all 
questions pertaining to the study protocol or all associated inquiries as deemed 
necessary by patient.  Once consent is provided by the patient, the RDC or Research 
Nurse will be allowed to enroll the patient on study. 
Written Informed Consent  
Written Informed Consent/Assent must be obtained for all patients who are potential 
study candidates before any study-specific tests or procedures are performed. 
Patients who meet general entry criteria will be asked to sign the study-specific, 
Institutional Review Board (IRB) approved Informed Consent form before any study-
specific tests or procedures are performed. Study personnel should explain that even if 
a patient agrees to participate in the study and signs an informed consent form, the 
surgeon may elect to withdraw that patient from the study for patient safety 
considerations.  
Enrollment 
Once a subject has been consented, she will be registered in CORE and considered 
enrolled into the study.   
Pre-Operative 
Prior to the patient’s scheduled procedure, record the patient’s demographic information 
(race, ethnicity, and date of birth), baseline information (height, weight, systolic/diastolic 
blood pressure, body mass index), incidence and severity of pain using the pain 
assessment tool (Appendix B), current pain medication use, comorbidities, previous 
surgeries, and administration of the MDASI questionnaire.   
Within 30 days prior to the planned procedure date, obtain serum blood tests per 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 17 of 39 
 
 
 
 
standard of care.  These will typically include: 
• SGOT, SGPT, and bilirubin 
• Creatinine 
• Platelet and white blood cells count 
• Hemoglobin and hematocrit 
• Serum or Urine Pregnancy test to be collected within 14 days of planned procedure 
date for women of child-bearing potential only 
Preoperative Randomization 
Once it has been determined that the patient meets all eligibility criteria, the patient is 
eligible for randomization. There will be a 1:1 randomization ratio as follows: local 
wound infiltration with bupivacaine immediately prior to wound closure (Arm 1), local 
wound infiltration with liposomal bupivacaine and 0.25% bupivacaine immediately 
prior to wound closure (Arm 2). 
All randomization will be carried out using REDCap stratified by surgeon. We expect 
that approximately 10 surgeons will participate. 
Methods and Procedure 
This study will be conducted at one center.  Following informed consent, patients will be 
prepared for surgery per standard institutional policy and practice.   
Standard operative procedures will be followed regardless of randomization assignment 
or participation in the study.  Data collection methods are described below. 
Postoperative data will be collected regarding incidence and severity of pain, medication 
use, and length of recovery and hospital stay.   
Discharge Procedure 
All patients will be evaluated on a daily basis by nursing staff to determine readiness for 
discharge.  
All patients will be discharged with the same analgesic opioid regimen (oxycodone 1-2 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 18 of 39 
 
 
 
 
tabs (5 mg) PO Q4 hours PRN: pain) unless medically contraindicated, in which case 
an alternative breakthrough medication will be prescribed.  
If patient is discharged before 96 hours post op, she will be contacted via IVR system or 
an electronic survey (via REDCap) will be sent by email or text message daily up to 96 
hours post op to record incidence and severity of pain. If the patient does not complete 
the questionnaire through the IVR system or REDCap, the study staff will contact the 
patient by phone and enter the information directly into REDCap. In the circumstance 
that the system is down, the patient refuses to respond electronically or there is no 
access to an electronic device, the use of paper forms will be permitted. Patients will be 
asked the following questions regarding their pain and opioid consumption: 
• Did you require any of your breakthrough pain medication yesterday? YES or NO 
• If YES how many tablets total did you take?  
• What was your highest level of pain yesterday on a scale from 0-10 (0 being no 
pain and 10 being the worst pain)? 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 19 of 39 
 
 
 
 
Patient Study Schedule 
 
 
 
 
 
Follow-Up Phase 
In-
patient 
After Discharge 
Baselinea 
Surgery 
Daily 
Week 1 
Day 3 
Week 1 
Day 7 
Weekly 
(weeks 
2-8) 
30-
day(+/-3 
days)h 
Informed Consent 
X 
 
 
 
 
 
 
CBC and Chemistry 
Panelb 
X 
 
 
 
 
 
 
Pregnancy Test (Serum 
or Urine)c 
X 
 
 
 
 
 
 
Randomization 
X 
 
 
 
 
 
 
Administration of 
Analgesic Agentd 
 
X 
 
 
 
 
 
MDASI Questionnairee 
X 
 
X 
X 
X 
X 
 
Opioid usef 
X 
X 
X 
 
 
Pain Assessmentg 
X 
X 
X 
 
 
Adverse Events 
 
X 
X 
 
 
 
X 
Complications 
 
X 
X 
 
 
 
X 
a. 
Baseline assessments to be collected within 30 days unless otherwise specified 
b. 
Serum blood tests to be performed per standard of care and may include: SGOT, SGPT, alkaline phosphatase, 
bilirubin, creatinine, platelets, white blood cell count, hemoglobin and hematocrit 
c. 
Serum or Urine pregnancy test to be obtained within 14 days of planned procedure date for women of child-
bearing potential only. 
d. 
Analgesic agent and administration to be determined by randomization arm. 
e. 
The MDASI Questionnaire may be administered via paper copy, sent by email or text message via REDCap, by 
interactive voice response (IVR) or phone calls depending on the patient location and preference. If the patient is 
contacted by phone or if the questionnaire is administered in person, the information will be directly entered into 
REDCap. In the circumstance that the system is down, the patient refuses to respond electronically or there is 
no access to an electronic device, the use of paper forms will be permitted.  
f. 
Opioid use will be assessed daily while in-patient. If patient leaves before 96 hours after surgery, opioid use will 
be assessed via IVR, phone calls or by email or text message via REDCap upon patient preference. If the 
patient is contacted by phone or the questionnaire is administered in person, the information will be directly 
entered into REDCap. In the circumstance that the system is down, the patient refuses to respond electronically 
or there is no access to an electronic device, the use of paper forms will be permitted.  
g. 
Pain will be assessed every 4 +/- 2 hours while patient is awake, up to 96 hours following surgery while in 
hospital. If patient is discharged before 96 hours post op, pain will be assessed once a day for up to 96 hours via 
IVR phone calls or by email or text message via REDCap. If the patient does not complete the pain assessment 
through the IVR system or REDCap, the study staff will contact the patient by phone and enter the information 
directly into REDCap. In the circumstance the system is down, the patient refuses to respond electronically or 
there is no access to an electronic device, the use of paper forms will be permitted.  
h. 
Post-operative complications and adverse events will be assessed within 30 days (+/- 3 days) of surgery by 
telephone, and electronic chart review. If the patient is contacted by phone or if the questionnaire is 
administered in person, the information will be directly entered into REDCap. In the circumstance that there is no 
access to an electronic device, the use of paper forms will be permitted.  


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 20 of 39 
 
 
 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 21 of 39 
 
 
 
 
Duration of Patient Participation 
Patients enrolled in the study will participate until the Patient Reported Outcomes, using 
the MD Anderson Symptom Inventory (MDASI), have been collected at the eighth 
postoperative week. If patients have been consented to BS99-094, then PRO and 
associated clinical and demographic data from 2015-1119 (PACIRA) will be shared with 
BS99-094.   
Statistical Considerations 
A sample size of 100 patients per arm will yield at least 80% power to detect an 
absolute increase of 20% in the proportion of patients opioid-free at 48 hours after end 
of surgery in the liposomal bupivacaine plus 0.25% bupivacaine arm (Arm 2) compared 
with the bupivacaine arm (Arm 1), regardless of the proportion of patients opioid-free in 
the 0.25% bupivacaine arm, with a 2-sided significance level of 0.05. Therefore, we will 
enroll a total sample size of 200 patients. Sample size calculations were performed 
using East 5.4 (Copyright © 2010, Cytel Inc., Cambridge, MA). 
Interim Analysis 
We will use the methods of Lan and DeMets [10] to perform an interim analysis for 
efficacy and futility once half the patients have been enrolled and evaluated at 48 
hours after the end of surgery. The interim analysis for futility will employ an O’Brien-
Fleming [11] stopping boundary with a nominal significance level of 0.7221, while the 
interim analysis of efficacy will employ an O’Brien-Fleming stopping boundary with a 
nominal significance level of 0.0031. The nominal significance level for the final analysis 
is 0.049. 
Final Analysis 
We will use descriptive statistics to summarize the demographic and clinical 
characteristics of patients overall and by treatment arm.  All patients will be followed for 
8 weeks and will be considered off-study at 8 weeks from surgery.  A final analysis will 
be performed once the last patient has been followed for 8 weeks. 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 22 of 39 
 
 
 
 
Primary Outcome 
We will compare the treatment arms with respect to the proportion of patients opioid-
free at 48 hours using the Cochran-Mantel-Haenszel test stratified by surgeon.  
Secondary Outcomes 
We will tabulate the number of opioid-free days by treatment arm, and we will use the 
Cochran-Mantel-Haenszel test stratified by surgeon to compare treatment arms with 
respect to the number of opioid-free days. 
We use descriptive statistics to summarize MEDD by treatment arm, and we will 
compare treatment arms with respect to mean MEDD using a 2-sample t-test. We will 
compare treatment arms with respect to median MEDD using the Wilcoxon rank sum 
test. We will similarly analyze the number of opioid doses per 24 hours. 
We will use descriptive statistics and graphical methods to summarize MDASI scores at 
each assessment time by treatment arm. We will also use repeated measures ANOVA 
to assess differences between treatment arms over time.  
We will calculate the area under the curve (AUC) for pain scores over time, and we will 
analyze pain scores using the same methods we use to analyze MEDD.  
We will use the Kaplan-Meier [12] product limit estimator to estimate the time to first 
post-operative opioid administration stratified by treatment arm, and we will compare 
treatment arms with the log-rank test. We will similarly analyze time to “discharge 
ready”. 
We will tabulate intraoperative opioid administration (opioid type and dose) by treatment 
arm, and we will use Fisher’s exact test to compare treatment arms with respect to the 
use of intraoperative opioids. 
We will tabulate complications by using the Clavien-Dindo Classification of Surgical 
Complications  (Appendix D) by treatment arm.  We will use Fisher’s exact test to 
compare treatment arms with respect to incidence of complications by grade. 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 23 of 39 
 
 
 
 
We will compare patients stated pain goal for the day between arm #1 and arm #2 
during the length of inpatient stay. 
Inclusion of Women and Minorities 
We will not exclude potential subjects from participating in this or any study solely on 
the basis of ethnic origin or socioeconomic status. Every attempt will be made to enter 
all eligible patients in this protocol and therefore address the study objectives in a 
patient population representative of the entire population treated by this institution. 
Adverse Events 
All adverse events (AE) and serious adverse events (SAE) will be monitored from the 
time of randomization through the hospital discharge.  
This trial will be comparing the efficacy of two FDA-approved drugs for this application 
(surgery) and uses the FDA-approved doses. The toxicity profile of each are well-
described in the package insert. 
Therefore, we will only collect AEs that meet the following criteria: grades 3 & 4 and 
deemed by the investigator as at least possibly related to either of the study drugs. The 
surgery itself is not a study procedure, however, we will collect complications as 
outlined under the secondary outcomes section. 
All Serious Adverse Events will be reported per institutional guidelines and processes 
and will include surgical complications should they meet the reporting requirements. An 
AE is defined as any undesirable clinical occurrence in a patient whether or not it is 
considered to be drug related. In addition, the definition of AE applies to any event with 
an onset post study procedure or to any underlying diseases, present at baseline that 
exacerbate in severity post study procedure. Therefore, an underlying disease that was  
present at the time of enrollment is not reported as an AE, but any increase in the 
severity of the underlying disease is to be reported as an AE. All reported AEs must be 
recorded in the REDCap database. A description of the event, including the start date, 
resolution date, action taken, and the outcome should be provided, along with the 
Investigator’s assessment of the relationship between the AE, the study treatment and 
the study procedure. Severity will be defined using CTCAE version 4.0.  


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 24 of 39 
 
 
 
 
A serious adverse event (SAE) is defined as an event that leads to:   
• Death due to any cause 
• Life-threatening condition 
• Results in persistent or significant disability/incapacity 
• Requires in-patient hospitalization or prolonged hospitalization 
• Necessitates an intervention to prevent a permanent impairment of a body function 
or permanent damage to a body structure 
• Results in congenital abnormality 
All SAE’s will be reported per standard institution guidelines and requirements. 
Drug-Related Adverse Event: an adverse event is considered to be drug-related when, 
in the judgment of the Investigator, the clinical event has a reasonable time sequence 
associated with use of the drug and is unlikely to be attributed to concurrent disease or 
other procedures or medications.  It is reasonable to believe that the drug directly caused 
or contributed to the adverse event.  
Procedure-Related Adverse Event: an adverse event is considered to be procedure-
related when, in the judgment of the Investigator; it is reasonable to believe that the 
event is associated with the assigned study procedure and is not specific to the drug 
used.  Other products, surgical techniques, or medications required specifically for the 
procedure are likely to have contributed to the occurrence of the event. 
Study Exit 
Once the patient has completed all Patient Reported Outcomes (PROs) (8 weeks 
postop) or has withdrawn, she should be exited from the study provided she does not 
have any conditions that require continued follow-up.  The date of exit and patient status 
should be recorded. 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 25 of 39 
 
 
 
 
Withdrawal of Subjects 
While study withdrawal is discouraged, patients may withdraw from the study at any 
time, with or without reason and without prejudice to further treatment.  In all cases of 
withdrawal, the reason(s) for withdrawal (if given) will be recorded upon study 
termination. 
In addition, the investigator may withdraw the subject due to any of the following 
situations: 
• adverse event 
• Any other reason determined by the investigator to be in the best interest of the 
subject. 
Subjects withdrawn due to an adverse event should be followed until the event has 
been resolved or is stable, if at all possible. 
Data Confidentiality Plan 
Study data will be collected and managed using REDCap [13] 
(Research Electronic Data Capture) electronic data capture tools hosted at MD 
Anderson. REDCap (www.project-redcap.org) is a secure, web-based application with 
controlled access designed to support data capture for research studies, providing: 1) 
an intuitive interface for validated data entry; 2) audit trails for tracking data 
manipulation and export procedures; 3) automated export procedures for seamless 
downloads to common statistical packages; and 4) procedures for importing data from 
external sources. In the case of multi-center studies REDCap uses Data Access Groups 
(DAGs) to ensure that personnel at each institution are blinded to the data from other 
institutions. REDCap (https://redcap.mdanderson.org) is hosted on a secure server by 
MD Anderson Cancer Center's Department of Research Information Systems & 
Technology Services. REDCap has undergone a Governance Risk & Compliance 
Assessment (05/14/14) by MD Anderson's Information Security Office and found to be 
compliant with HIPAA, Texas Administrative Codes 202-203, University of Texas Policy 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 26 of 39 
 
 
 
 
165, federal regulations outlined in 21CFR Part 11, and UTMDACC Institutional Policy 
#ADM0335. Those having access to the data file include the study PI and research 
team personnel. Users are authenticated against MDACC's Active Directory system. 
External collaborators are given access to projects once approved by the project 
sponsor. The application is accessed through Secure Socket Layer (SSL). All protected 
health information (PHI) will be removed from the data when it is exported from 
REDCap for analysis. All dates for a given patient will be shifted by a randomly 
generated number between 0 and 364, thus preserving the distance between dates. 
Dates for each patient will be shifted by a different randomly generated number. 
Following publication study data will be archived in REDCap.  
Data Elements to be collected may include the following: 
Electronic CRFs will be also be used to collect the following data: 
Pre-Operative 
• Demographic information  
• Pre-operative vitals 
• Pre-operative labs 
• Pain incidence and severity  
• Current pain medication taken by patient 
• Pre-operative pain medication 
Intraoperative 
• 
Date of surgery  
• Blood loss 
• Procedure time (initial incision to closure) 
• Urine output 
• Blood transfusions 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 27 of 39 
 
 
 
 
• Intraoperative opioid administration  
Post-Operative 
• 
Tumor pathology: Malignant or benign.  
Recovery room 
• Severity and incidence of pain every 4 +/- 2 hours on day of surgery.  
• SAEs and AEs will be recorded per occurrence on day of surgery.  
• Any postoperative complications  
In-patient Floor  
• Incidence and severity of pain every 4 +/- 2 hours every day.  
• SAEs and AEs will be recorded per occurrence.  
• Any complications will be recorded per occurrence.  
• Patient Reported Outcomes with MDASI daily while admitted.  
• Pain goals daily while admitted.  
Discharge 
• Post op pain incidence and severity if patient is discharged before 96 hours post-
surgery.  
• Opioid use if patient is discharged before 96 hours post-surgery.  
• Length of stay 
• Patient Reported Outcomes with MDASI will be collected on day 3 and day 7 after 
discharge, and then weekly to complete 8 weeks from the date of surgery. For safety 
purposes, a notification to the primary surgical team will be given within 24 hours for 
any patient that reports pain, sadness or shortness of breath in the severe range 
(>=7) 
• Any postoperative complications prior to discharge  
• “Ready for discharge” date will be recorded 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 28 of 39 
 
 
 
 
Follow-up 
• Patients will be contacted within 30 days (+/- 3 days) of surgery by telephone, 
electronic correspondence, or clinic visit, depending on patient access to the 
hospital. SAEs, AEs, and postoperative complications will be assessed at follow up. 
Study Conduct & the Declaration of Helsinki 
The Physician Preference Study will be performed in accordance with the relevant parts 
of Title 21 CFR Parts 812, 50, 54, 56 and ISO 14155-1 / 14155-2.1; the ICH Guidelines 
for Good Clinical Practices (E6), the Declaration of Helsinki, and any regional and/or 
national regulations. 
Data Safety Monitoring Board (DSMB) 
The monitoring of this trial will be provided by MD Anderson Cancer Center DSMB.  
Amending the Protocol 
An Investigator may consider making changes to the protocol.  All changes must be 
submitted and subsequently approved by the MD Anderson IRB. The investigative site 
(MD Anderson) must send PACIRA a copy of the IRB approval letter for the protocol 
amendment. 
Emergency Actions 
PACIRA accepts the right of the Investigator to deviate from the protocol in an 
emergency when necessary to safeguard the life or the physical well being of a study 
patient. The Investigator must give notice of any emergency deviations and justification 
for the deviation to PACIRA and the IRB as quickly as possible after the episode, in any 
event no later than 24 hours after the emergency. 
Protocol Deviations 
For purposes related to this study, a protocol deviation is defined as an event where the 
Clinical Investigator or site personnel did not conduct the study according to the protocol 
but does not affect the safety of the patient or the integrity of the data. 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 29 of 39 
 
 
 
 
Investigators shall be required to obtain prior approval from PACIRA clinical study 
management before initiating significant deviations from the protocol, except where 
necessary to protect the life or physical well-being of a subject in an emergency.  Such 
approval shall be documented in writing and maintained in clinical study management 
and Investigator files on the REDCap database.  Prior approval is generally not 
expected in situations where unforeseen circumstances are beyond the Investigator’s 
control, (e.g. subject was not available for scheduled follow-up office visit, blood sample 
lost by laboratory, etc.); however, the event is still considered a deviation and will be 
reported via the appropriate CRF. 
Significant deviations must be reported to PACIRA regardless of whether medically 
justifiable, pre-approved by PACIRA or taken to protect the subject in an emergency.  
Subject specific deviations will be reported on the Protocol Deviation case report form.  
Investigators will also adhere to procedures for reporting study deviations to their IRB in 
accordance with their specific IRB reporting policies and procedures. 
Regulations require that Investigators maintain accurate, complete and current records, 
including documents showing the dates of and reasons for each deviation from the 
protocol.  Minor Deviations that continue to occur at an investigational site may be re-
classified as violations if corrective action is not taken to secure future compliance to the 
protocol. 
Violations will be reported per institution guidelines and requirements.  
Coverage of Expenses 
The treated subjects will not be reimbursed or compensated for participating in the 
Study. 
Confidentiality  
Confidentiality of subjects will be maintained throughout the Study.  A unique 
identification code will be assigned to each subject participating in this Study.  Any data 
that may be published in abstracts, scientific journals, or presented at medical meetings 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 30 of 39 
 
 
 
 
may reference a unique subject code and will not reveal the subject’s identity.  The 
CRO representative will make every reasonable effort to protect the confidentiality of the 
subjects participating in the Study. 
Institutional Review Board/Ethics Committee 
A copy of the protocol, proposed Informed Consent form, other written patient 
information and any proposed advertising material must be submitted to the IRB for 
written approval.  A copy of the written IRB approval of the protocol and Informed 
Consent form must be received by PACIRA before recruitment of patients into the 
study. 
The Investigator must submit and, where necessary, obtain approval from the IRB for all 
subsequent significant protocol amendments and significant changes to the Informed 
Consent form.  The Investigator should notify the IRB of deviations from the protocol or 
SAEs occurring at the site and other SAE reports received from PACIRA in accordance 
with local procedures. 
The Investigator will be responsible for obtaining annual IRB approval and/or renewal 
throughout the duration of the study. Copies of the Investigator’s reports and the IRB 
continuance of approval must be sent to PACIRA.  
Source Documentation 
The Principal Investigator must maintain detailed source documents on all Study 
patients who are enrolled in the Study or who undergo screening.  Source documents 
include patient medical records, hospital charts, clinic charts, Investigator’s Study files, 
as well as the results of diagnostic tests (e.g., laboratory tests). 
The following minimum information should be recorded in the patient’s medical records: 
• The date the patient entered the Study and the patient number 
• The Study protocol number 
• The date that informed consent was obtained 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 31 of 39 
 
 
 
 
• Evidence that the patient meets Study eligibility requirements (e.g., medical history, 
Study procedures and/or evaluations) 
• Evidence that required procedures and/or evaluations were completed 
• Opioid use 
•  All lab reports taken for this study 
• Occurrence and status of any Adverse Events 
• The date the patient exited the Study, and a notation as to whether the patient 
completed the Study or was discontinued, including the reason for discontinuation. 
Record Retention 
The Investigator will maintain all essential study documents and source documentation, 
in original format that support the data collected on the study patients in compliance 
with the ICH/GCP guidelines. Study data will be archived in REDCap.  
Investigator Responsibilities 
• Agree to sign and adhere to the Investigator Agreement 
• Agree to participate in Investigator meetings as scheduled by PACIRA. 
• Be willing to provide required assessments for analysis 
• Be willing to perform and be capable of performing treatment procedures as outlined 
in this protocol 
• Comply with all required elements of this protocol (e.g., perform testing and follow-
up as specified, especially during personnel transitions) and supply material suitable 
for quantitative analysis 
• Agree to obtain written Informed Consent before any study specific procedures are 
performed  
• Complete all CRFs prior to scheduled monitoring visits 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 32 of 39 
 
 
 
 
References 
1. 
Nelson G, Kalogera E, Dowdy SC. Enhanced recovery pathways in gynecologic 
oncology. Gynecol Oncol 2014;135:586-594 
2. 
Kehlet H, Enhanced Recovery After Surgery (ERAS): good for now, but what 
about the future? Can J Anaesth, 2015;62:99-104 
3. 
Oderda GM, Gan TJ, Johnson BH, Robinson SB. Effect of opioid-related adverse 
events on outcomes in selected surgical patients. J Pain Palliat Care 
Pharmacother, 2013;27:62-70 
4. 
Nick AM, Meyer L, Iniesta MD, Lasala J, Harris M, Palmer L, Earles TW, Cain 
KE, Washington L, Munsell M, Ramirez PT.  Implementation of an enhanced 
recovery program at a tertiary cancer center.  World Congress of Enhanced 
Recovery After Surgery and Perioperative Medicine.  Washington, DC May 2015 
5. 
Basch E., Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, et al., 
Recommendations for incorporating patient-reported outcomes into clinical 
comparative effectiveness research in adult oncology. J Clin Oncol, 
2012;30:4249-55 
6. 
Wu AW, Snyder C, Clancy CM, Steinwachs DM. Adding the patient perspective 
to comparative effectiveness research. Health Aff (Millwood), 2010;29:1863-71 
7. 
Reeve BB, Mitchell SA, Dueck AC, Basch E, Cella D, Reilly CM, et al., 
Recommended patient-reported core set of symptoms to measure in adult cancer 
treatment trials. J Natl Cancer Inst, 2014;106(7) pii: dju129. doi: 
10.1093/jnci/dju129 
8. 
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al., 
Development of the National Cancer Institute's patient-reported outcomes 
version of the common terminology criteria for adverse events (PRO-CTCAE). J 
Natl Cancer Inst 2014;106(9). pii: dju244. doi: 10.1093/jnci/dju244 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 33 of 39 
 
 
 
 
9. 
0-10 Numeric Pain Rating Scale: From McCaffery M, Pasero C. Pain: Clinical 
Manual, St Louis, 1999, P. 16 
10. 
Lan KKG, DeMets DL.  Discrete sequential boundaries for clinical 
trial.  Biometrika 1983;70:659-663 
11.      O’Brien PC, Fleming TR.  A multiple testing procedure for clinical 
trials.  Biometrics 1979;35:549-556 
12.      Kaplan EL, Meier P.  Nonparametric estimation from incomplete 
observations.  Journal of the American Statistical Association 1958; 53:457-481 
13.      Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG, Research 
electronic data capture (REDCap) - A metadata-driven methodology and 
workflow process for providing translational research informatics support, J 
Biomed Inform. 2009;42:377-81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 34 of 39 
 
 
 
 
Abbreviations 
 
ERP  
Enhanced Recovery Pathway 
MDASI 
MD Anderson Symptom Inventory 
MEDD 
Morphine Equivalent Daily Dose 
 
POD  
Post-Operative Day 
 
PROs  
Patient Reported Outcomes 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 35 of 39 
 
 
 
 
Appendix A: MD Anderson Symptom Inventory – GYN Cancer (MDASI-GYN)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 36 of 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 37 of 39 
 
 
 
 
Appendix B: Pain Assessment Tool 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 38 of 39 
 
 
 
 
Appendix C:  Discharge Ready Criteria 
 
• Ambulates 4 times per day 
o Date that patient accomplished ambulation criteria 
• Eats all meals sitting up in a chair 
o Date that patient ate all meals sitting up in a chair  
• Tolerates 3 regular meals per day  
o Date that patient tolerated a regular diet 
• Voiding independently (if Foley catheter is due to be removed on POD1) 
o Date that patient voided independently  
• Reports adequate pain control with oral medications 
o Date that patient reported adequate pain control with oral medications  
• Criteria for discharge met 
o Date criteria for discharge was met 
 
 


 
 
2015-1119 
 
 
September 10, 2018 
 
 
Page 39 of 39 
 
 
 
 
Appendix D:  The Clavien-Dindo Classification of Surgical Complications 
 
Grade I: Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic and radiological interventions. 
Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, 
diuretics and electrolytes and physiotherapy. This grade also includes wound infections 
opened at the bedside. 
 
Grade II: Requiring pharmacological treatment with drugs other than such allowed for 
grade I complications. Blood transfusions and total parenteral nutrition are also 
included. 
 
Grade III:  
 
Requiring surgical, endoscopic or radiological intervention 
 
Grade IIIa: intervention not under general anesthesia 
 
Grade IIIb: intervention under general anesthesia 
 
Grade IV: Life-threatening complication (including CNS complications)‡ requiring 
IC/ICU-management 
 
Grade IVa: single organ dysfunction (including dialysis) 
 
Grade IVb: Multi-organ dysfunction 
 
Grade V: Death of a patient. If the patients suffers from a complication at the time of 
discharge, the suffix “d” (for ‘disability’) is added to the respective grade of complication. 
This label indicates the need for a follow-up to fully evaluate the complication. 
 
‡ brain hemorrhage, ischemic stroke, subarrachnoidal bleeding,but excluding transient 
ischemic attacks (TIA);IC: Intermediate care; ICU: Intensive care unit.